Minimal clinically important difference on the Beck Depression Inventory - II according to the patient's perspective

K S Button, D Kounali, Laura Thomas, N J Wiles, T J Peters, N J Welton, A E Ades, Glyn Lewis

Research output: Contribution to journalArticle

55 Citations (Scopus)
46 Downloads (Pure)

Abstract

BACKGROUND: The Beck Depression Inventory, 2nd edition (BDI-II) is widely used in research on depression. However, the minimal clinically important difference (MCID) is unknown. MCID can be estimated in several ways. Here we take a patient-centred approach, anchoring the change on the BDI-II to the patient's global report of improvement.

METHOD: We used data collected (n = 1039) from three randomized controlled trials for the management of depression. Improvement on a 'global rating of change' question was compared with changes in BDI-II scores using general linear modelling to explore baseline dependency, assessing whether MCID is best measured in absolute terms (i.e. difference) or as percent reduction in scores from baseline (i.e. ratio), and receiver operator characteristics (ROC) to estimate MCID according to the optimal threshold above which individuals report feeling 'better'.

RESULTS: Improvement in BDI-II scores associated with reporting feeling 'better' depended on initial depression severity, and statistical modelling indicated that MCID is best measured on a ratio scale as a percentage reduction of score. We estimated a MCID of a 17.5% reduction in scores from baseline from ROC analyses. The corresponding estimate for individuals with longer duration depression who had not responded to antidepressants was higher at 32%.

CONCLUSIONS: MCID on the BDI-II is dependent on baseline severity, is best measured on a ratio scale, and the MCID for treatment-resistant depression is larger than that for more typical depression. This has important implications for clinical trials and practice.

Original languageEnglish
Pages (from-to)3269-3279
Number of pages10
JournalPsychological Medicine
Volume45
Issue number15
Early online date13 Jul 2015
DOIs
Publication statusPublished - 1 Nov 2015

Fingerprint

Depression
Equipment and Supplies
Emotions
Treatment-Resistant Depressive Disorder
Minimal Clinically Important Difference
Antidepressive Agents
Randomized Controlled Trials
Clinical Trials
Research

Cite this

Minimal clinically important difference on the Beck Depression Inventory - II according to the patient's perspective. / Button, K S; Kounali, D; Thomas, Laura; Wiles, N J; Peters, T J; Welton, N J; Ades, A E; Lewis, Glyn.

In: Psychological Medicine, Vol. 45, No. 15, 01.11.2015, p. 3269-3279.

Research output: Contribution to journalArticle

Button, K S ; Kounali, D ; Thomas, Laura ; Wiles, N J ; Peters, T J ; Welton, N J ; Ades, A E ; Lewis, Glyn. / Minimal clinically important difference on the Beck Depression Inventory - II according to the patient's perspective. In: Psychological Medicine. 2015 ; Vol. 45, No. 15. pp. 3269-3279.
@article{a18dde7b484044e7bdf2537c64f55b16,
title = "Minimal clinically important difference on the Beck Depression Inventory - II according to the patient's perspective",
abstract = "BACKGROUND: The Beck Depression Inventory, 2nd edition (BDI-II) is widely used in research on depression. However, the minimal clinically important difference (MCID) is unknown. MCID can be estimated in several ways. Here we take a patient-centred approach, anchoring the change on the BDI-II to the patient's global report of improvement.METHOD: We used data collected (n = 1039) from three randomized controlled trials for the management of depression. Improvement on a 'global rating of change' question was compared with changes in BDI-II scores using general linear modelling to explore baseline dependency, assessing whether MCID is best measured in absolute terms (i.e. difference) or as percent reduction in scores from baseline (i.e. ratio), and receiver operator characteristics (ROC) to estimate MCID according to the optimal threshold above which individuals report feeling 'better'.RESULTS: Improvement in BDI-II scores associated with reporting feeling 'better' depended on initial depression severity, and statistical modelling indicated that MCID is best measured on a ratio scale as a percentage reduction of score. We estimated a MCID of a 17.5{\%} reduction in scores from baseline from ROC analyses. The corresponding estimate for individuals with longer duration depression who had not responded to antidepressants was higher at 32{\%}.CONCLUSIONS: MCID on the BDI-II is dependent on baseline severity, is best measured on a ratio scale, and the MCID for treatment-resistant depression is larger than that for more typical depression. This has important implications for clinical trials and practice.",
author = "Button, {K S} and D Kounali and Laura Thomas and Wiles, {N J} and Peters, {T J} and Welton, {N J} and Ades, {A E} and Glyn Lewis",
year = "2015",
month = "11",
day = "1",
doi = "10.1017/S0033291715001270",
language = "English",
volume = "45",
pages = "3269--3279",
journal = "Psychological Medicine",
issn = "1469-8978",
publisher = "Cambridge University Press",
number = "15",

}

TY - JOUR

T1 - Minimal clinically important difference on the Beck Depression Inventory - II according to the patient's perspective

AU - Button, K S

AU - Kounali, D

AU - Thomas, Laura

AU - Wiles, N J

AU - Peters, T J

AU - Welton, N J

AU - Ades, A E

AU - Lewis, Glyn

PY - 2015/11/1

Y1 - 2015/11/1

N2 - BACKGROUND: The Beck Depression Inventory, 2nd edition (BDI-II) is widely used in research on depression. However, the minimal clinically important difference (MCID) is unknown. MCID can be estimated in several ways. Here we take a patient-centred approach, anchoring the change on the BDI-II to the patient's global report of improvement.METHOD: We used data collected (n = 1039) from three randomized controlled trials for the management of depression. Improvement on a 'global rating of change' question was compared with changes in BDI-II scores using general linear modelling to explore baseline dependency, assessing whether MCID is best measured in absolute terms (i.e. difference) or as percent reduction in scores from baseline (i.e. ratio), and receiver operator characteristics (ROC) to estimate MCID according to the optimal threshold above which individuals report feeling 'better'.RESULTS: Improvement in BDI-II scores associated with reporting feeling 'better' depended on initial depression severity, and statistical modelling indicated that MCID is best measured on a ratio scale as a percentage reduction of score. We estimated a MCID of a 17.5% reduction in scores from baseline from ROC analyses. The corresponding estimate for individuals with longer duration depression who had not responded to antidepressants was higher at 32%.CONCLUSIONS: MCID on the BDI-II is dependent on baseline severity, is best measured on a ratio scale, and the MCID for treatment-resistant depression is larger than that for more typical depression. This has important implications for clinical trials and practice.

AB - BACKGROUND: The Beck Depression Inventory, 2nd edition (BDI-II) is widely used in research on depression. However, the minimal clinically important difference (MCID) is unknown. MCID can be estimated in several ways. Here we take a patient-centred approach, anchoring the change on the BDI-II to the patient's global report of improvement.METHOD: We used data collected (n = 1039) from three randomized controlled trials for the management of depression. Improvement on a 'global rating of change' question was compared with changes in BDI-II scores using general linear modelling to explore baseline dependency, assessing whether MCID is best measured in absolute terms (i.e. difference) or as percent reduction in scores from baseline (i.e. ratio), and receiver operator characteristics (ROC) to estimate MCID according to the optimal threshold above which individuals report feeling 'better'.RESULTS: Improvement in BDI-II scores associated with reporting feeling 'better' depended on initial depression severity, and statistical modelling indicated that MCID is best measured on a ratio scale as a percentage reduction of score. We estimated a MCID of a 17.5% reduction in scores from baseline from ROC analyses. The corresponding estimate for individuals with longer duration depression who had not responded to antidepressants was higher at 32%.CONCLUSIONS: MCID on the BDI-II is dependent on baseline severity, is best measured on a ratio scale, and the MCID for treatment-resistant depression is larger than that for more typical depression. This has important implications for clinical trials and practice.

U2 - 10.1017/S0033291715001270

DO - 10.1017/S0033291715001270

M3 - Article

VL - 45

SP - 3269

EP - 3279

JO - Psychological Medicine

JF - Psychological Medicine

SN - 1469-8978

IS - 15

ER -